Diabetes Insipidus

Diabetes insipidus (DI) is a rare disorder of water balance (prevalence ~1 in 25,000) characterized by hypotonic polyuria and compensatory polydipsia due to either deficient arginine vasopressin (AVP) secretion (central DI / AVP deficiency) or renal insensitivity to AVP (nephrogenic DI / AVP resistance). [1-2] The condition was recently renamed: central DI → AVP deficiency (AVP-D) and nephrogenic DI → AVP resistance (AVP-R) to avoid confusion with diabetes mellitus. [3-4]

1. History

• Polyuria: Quantify urine output — typically >3 L/day in adults (>30 mL/kg/day); can exceed 8–10 L/day in complete DI [1][5]
• Polydipsia: Intense, unrelenting thirst with preference for cold water; ask about nighttime fluid intake and nocturia frequency [6]
• Onset: Abrupt onset favors central DI (especially post-surgical or post-traumatic); gradual onset may suggest nephrogenic DI or primary polydipsia [6-7]
• Timing: Post-pituitary surgery DI typically appears within 24–48 hours; may follow a triphasic pattern (DI → SIADH → permanent DI) [8]
• Triggers: Recent head trauma, neurosurgery, new medications (especially lithium), pregnancy [1][9]
• Important negatives: Absence of glucosuria (rules out osmotic diuresis from diabetes mellitus), absence of psychiatric history or excessive health-conscious water intake (argues against primary polydipsia) [7]

2. Alarm Features

• Severe hypernatremia (Na >160 mmol/L): risk of seizures, coma, osmotic demyelination syndrome [5][10]
• Altered mental status, lethargy, confusion — suggests significant dehydration/hyperosmolality [11-12]
• Inability to access water (postoperative, intubated, impaired consciousness) — places patient at extreme risk for rapid dehydration [13-14]
• Adipsic DI (loss of thirst): absence of compensatory polydipsia leads to severe chronic dehydration [14-15]
• New-onset DI with headache, visual field deficits, or anterior pituitary dysfunction — suggests underlying mass lesion (craniopharyngioma, germinoma, metastasis) [16-17]
• Triphasic response post-pituitary surgery: initial DI → hyponatremia (SIADH phase) → permanent DI [8]

3. Medications

Causative medications (nephrogenic DI)

• Lithium — most common drug cause (~10% of long-term users); may be only partly reversible after prolonged use [9][18-19]
• Demeclocycline, foscarnet, amphotericin B, cidofovir, ifosfamide, cisplatin [18]

Treatments — Central DI

• Desmopressin (DDAVP) — first-line; oral starting dose 0.05 mg BID, titrate to 0.1–0.8 mg/day in divided doses; intranasal 10–40 mcg/day; IV/SC for acute settings [20-21]
• The "desmopressin escape" method (delaying a dose to allow breakthrough aquaresis 1–2×/week) reduces hyponatremia risk [4][15][22]

Treatments — Nephrogenic DI

• Thiazide diuretics (hydrochlorothiazide) — paradoxical antidiuresis via volume contraction [23-24]
• Amiloride — especially for lithium-induced NDI (blocks lithium entry via ENaC) [9][25]
• NSAIDs (indomethacin) — reduce prostaglandin-mediated antagonism of AVP; use in severe cases [24][26]
• Low-sodium, low-protein diet as adjunct [24]

Contraindications/Cautions

• Desmopressin is ineffective in nephrogenic DI [20][27]
• Desmopressin is contraindicated with CrCl <50 mL/min [20]
• Major adverse effect of desmopressin: dilutional hyponatremia — can be life-threatening if fluid intake is not managed [28]

4. Diet

• Low-sodium diet (especially nephrogenic DI) — reduces solute load and obligate urine output [24]
• Adequate free water access is critical; patients must be able to drink to thirst at all times [2][15]
• Low-protein diet may reduce renal solute load in nephrogenic DI [24]
• During acute illness with vomiting/diarrhea, IV hypotonic fluids (D5W) may be needed to prevent dehydration [29]

5. Review of Systems

• Neurologic: Headache, visual changes, cognitive decline (mass lesion or severe hypernatremia)
• Endocrine: Symptoms of anterior pituitary deficiency — fatigue, cold intolerance, amenorrhea, decreased libido (suggests panhypopituitarism) [16][30]
• GI: Constipation (dehydration) [11]
• Psychiatric: Screen for mood disorders (lithium use), anxiety, depression (common comorbidity in DI patients) [28]
• Dermatologic: Dry skin (dehydration) [11]
• Genitourinary: Nocturia frequency, enuresis

6. Collateral History and Family History

• Family history of polyuria/polydipsia — familial central DI (AVP gene mutations, autosomal dominant) or congenital nephrogenic DI (AVPR2 mutations, X-linked; AQP2 mutations, autosomal recessive) [11][23]
• Familial forms account for ~1% of central DI cases [23]
• Congenital nephrogenic DI: >280 disease-causing mutations identified [23]
• Collateral from caregivers is essential in patients with impaired consciousness, pediatric patients, or those with cognitive impairment who cannot report symptoms [13]
• Medication reconciliation — confirm lithium use, duration, and levels [9]

7. Risk Factors

• Pituitary/hypothalamic surgery — most common acquired cause; DI occurs in ~10.7% of transsphenoidal surgeries (4.5% permanent) [31-32]
• Craniopharyngioma — highest risk (46.3% post-surgical DI) [31]
• Head trauma — especially with basilar skull fractures [1][14]
• CNS tumors: Germinoma, metastases, Langerhans cell histiocytosis [16-17]
• Autoimmune/inflammatory: Lymphocytic infundibuloneurohypophysitis, sarcoidosis, IgG4-related disease [1][14]
• Idiopathic: 30–50% of central DI cases; thought to be autoimmune; requires serial MRI follow-up [11][16]
• Lithium therapy (nephrogenic DI) — risk increases with duration; may affect ~10% of long-term users [9][19]
• Electrolyte disorders: Hypercalcemia, hypokalemia (nephrogenic DI) [18]
• Pregnancy: Increased placental vasopressinase can unmask or cause gestational DI [7][15]
• Intraoperative risk factors: CSF leak, gross total resection, pituitary stalk manipulation [31-32]

8. Differential Diagnosis

• Primary polydipsia — excessive fluid intake despite normal AVP; more common in psychiatric patients or health-conscious individuals; urine can concentrate with water deprivation [7][33]
• Diabetes mellitus — osmotic diuresis from glucosuria; check glucose and urine glucose [11]
• Osmotic diuresis — mannitol, urea, post-obstructive diuresis, high-protein tube feeds
• Chronic kidney disease — impaired concentrating ability
• Hypercalcemia / Hypokalemia — acquired nephrogenic DI [18]
• Gestational DI — onset in 2nd/3rd trimester; resolves postpartum [7]
• Beer potomania / Tea-and-toast diet — low solute intake causing dilute polyuria

Distinguishing features: Central DI has abrupt onset, preference for cold water, nocturia with nighttime fluid intake; primary polydipsia tends to have gradual onset and fluctuating symptoms [6]

9. Past Medical History

• Prior pituitary surgery, cranial radiation, or head trauma
• Known pituitary adenoma, craniopharyngioma, or other sellar/suprasellar lesion
• Autoimmune conditions (may predispose to autoimmune hypophysitis)
• Bipolar disorder or other conditions treated with lithium
• Prior episodes of hypernatremia or hyponatremia (if on desmopressin)
• Chronic kidney disease (affects desmopressin clearance and nephrogenic DI risk) [20]
• Pregnancy history (gestational DI)

10. Physical Exam

• Vital signs: Tachycardia, orthostatic hypotension (dehydration); weight loss
• Hydration status: Dry mucous membranes, decreased skin turgor (though turgor may be preserved in hypernatremic dehydration), sunken eyes [29]
• Neurologic: Mental status changes (lethargy → confusion → seizures → coma with severe hypernatremia); visual field testing (bitemporal hemianopia suggests sellar mass) [11-12]
• Fundoscopic exam: Papilledema if mass effect present
• Note: In compensated DI with intact thirst, physical exam may be entirely normal [14]

11. Lab Studies

Initial workup

• Serum sodium and osmolality — Na >145 mmol/L reliably confirms AVP deficiency; Na <135 mmol/L essentially rules it out [6]
• Urine osmolality and specific gravity — dilute urine (<300 mOsm/kg, specific gravity <1.005) in the setting of elevated serum osmolality is diagnostic of DI [1][5]
• Serum glucose — rule out osmotic diuresis
• Serum calcium, potassium — hypercalcemia and hypokalemia cause nephrogenic DI [18]
• BUN/creatinine — assess renal function
• Plasma copeptin (if available): Basal copeptin >21.4 pmol/L → nephrogenic DI; copeptin >5.6 pmol/L → rules out central DI (suggests primary polydipsia) [6][15][34]

Monitoring on treatment

• Serum sodium every 1–3 months on desmopressin; more frequently during titration [20][22]
• 24-hour urine volume to assess treatment response

12. Imaging

• MRI of the pituitary/hypothalamus (with and without gadolinium) — first-line imaging for all new central DI [15][17]
  • Loss of posterior pituitary bright spot (T1 hyperintensity) — characteristic of central DI [15]
  • Pituitary stalk thickening — suggests inflammatory, infiltrative, or neoplastic process [15][35]
  • Evaluate for mass lesions: craniopharyngioma, germinoma, metastasis, Langerhans cell histiocytosis [17]
• Serial MRI recommended in idiopathic central DI — tumors may not be evident at initial presentation; follow every 6 months for up to 3 years [16][35]
• Imaging is generally not needed for clearly drug-induced nephrogenic DI (e.g., lithium) or post-surgical DI with known etiology

13. Special Tests

Water deprivation test (classic but being supplanted)

• 8-hour fluid deprivation → measure plasma and urine osmolality → administer DDAVP 2 mcg IM → measure urine osmolality hourly for 4 hours [16]
• Central DI: Urine concentrates >800 mOsm/kg after DDAVP
• Nephrogenic DI: Urine remains <300 mOsm/kg after DDAVP
• Diagnostic accuracy only ~77% (especially poor for partial central DI vs. primary polydipsia) [36]

Copeptin-based stimulation tests (emerging gold standard)

• Hypertonic saline-stimulated copeptin: Copeptin >4.9 pmol/L at Na ≥150 mmol/L → primary polydipsia; diagnostic accuracy 96.5% [36]
• Arginine-stimulated copeptin: Diagnostic accuracy 93%; simpler protocol, better tolerated [33][37]

The following figure from Fenske et al. (NEJM 2018) demonstrates the superior diagnostic accuracy of hypertonic saline-stimulated copeptin (AUC 0.97) compared to the traditional water deprivation test (AUC 0.65):

Novel diagnostic score (2025): Incorporates basal plasma sodium, osmolality, copeptin, nocturia, onset pattern, MRI findings, and pituitary history — may allow diagnosis without dynamic testing [6]

14. ECG

• ECG is not a primary diagnostic tool for DI but should be obtained if:
  • Severe hypernatremia — risk of cardiac arrhythmias
  • Hypokalemia or hypercalcemia — associated electrolyte abnormalities causing nephrogenic DI
  • Concurrent lithium use — monitor for lithium-related cardiac effects
• No pathognomonic ECG findings for DI itself

15. Assessment

Severity stratification

• Mild/compensated: Intact thirst, adequate water access, normal sodium — managed outpatient
• Moderate: Significant polyuria (>5 L/day), nocturia disrupting sleep, mild hypernatremia
• Severe/decompensated: Na >155 mmol/L, altered mental status, inability to drink, adipsic DI — medical emergency [5][13]

Typical presentation: Abrupt onset of polyuria and polydipsia, often with nocturia and preference for cold water, in the setting of pituitary surgery, head trauma, or new mass lesion [1]

Atypical presentations: Partial DI with only mild polyuria; adipsic DI presenting with severe hypernatremia without polydipsia; triphasic response post-surgery [8][14]

Complications: Severe dehydration, hypernatremic encephalopathy, seizures, osmotic demyelination syndrome (from overly rapid correction), bladder distension, hydronephrosis [5][11]

16. Treatment Plan

Acute/Emergency (severe hypernatremia or decompensated DI)

• IV desmopressin 1–2 mcg IV/SC for central DI — short-acting, easily titratable [13][38]
• Free water replacement: Calculate free water deficit; administer D5W IV; correct sodium at ≤10–12 mEq/L per 24 hours to avoid cerebral edema [5][10]
• Frequent sodium monitoring (every 2–4 hours initially) [10]
• Ensure unrestricted access to water if patient can drink

Chronic — Central DI

• Desmopressin oral: Start 0.05 mg BID, titrate to 0.1–0.8 mg/day (range 0.1–1.2 mg/day) [20]
• Desmopressin intranasal: 10–40 mcg/day [21]
• Employ desmopressin escape (skip a dose 1–2×/week to allow aquaresis) to prevent hyponatremia [4][15][22]
• Congenital DI may require higher doses (median ~600 mcg oral equivalent/day vs. 200 mcg for acquired) [39]

Chronic — Nephrogenic DI

• Remove offending agent if possible (e.g., lithium — though may be only partly reversible after long-term use) [9][18]
• Hydrochlorothiazide 25–50 mg/day ± amiloride 5–10 mg/day (especially for lithium-induced NDI) [9][24-25]
• Indomethacin 25–50 mg TID for severe cases [24][26]
• Low-sodium diet (<2 g/day), adequate hydration [24]

17. Disposition

Admission criteria

• Severe hypernatremia (Na >155 mmol/L) or symptomatic hypernatremia [10][13]
• Altered mental status, hemodynamic instability
• Inability to maintain oral hydration (vomiting, impaired consciousness)
• New-onset DI requiring workup for underlying etiology (mass lesion)
• Post-surgical DI requiring close sodium and fluid monitoring [8]
• Adipsic DI — requires inpatient establishment of fluid/desmopressin regimen [15][22]

Discharge criteria

• Stable sodium, adequate oral intake, established desmopressin dose
• Patient educated on medication use, fluid management, and warning signs

Specialist consultation

• Endocrinology — all new diagnoses of DI for etiologic workup and treatment optimization
• Neurosurgery — if mass lesion identified or post-surgical DI
• Nephrology — refractory nephrogenic DI or significant renal impairment

18. Follow Up / Return Precautions

Follow-up timing

• Within 1–2 weeks after discharge or initiation of desmopressin for sodium check and dose titration [20]
• Every 1–3 months once stable, with serum sodium monitoring [22]
• Serial MRI every 6 months for up to 3 years in idiopathic central DI to surveil for emerging pathology [16][35]

Return precautions — instruct patients to seek immediate care for:

• Decreased urine output with headache, nausea, confusion (suggests hyponatremia from desmopressin overtreatment) [28]
• Inability to keep up with fluid intake (vomiting, illness)
• Severe thirst with decreased consciousness
• New headache, visual changes, or neurologic symptoms (mass effect)

Patient counseling

• Always carry water and desmopressin; wear medical alert identification
• Understand the desmopressin escape technique [4][22]
• During intercurrent illness (fever, GI illness), increase fluid intake and monitor closely; consider holding desmopressin if hyponatremia risk is high [20]
• Expected recovery: Central DI post-surgery may be transient (resolves in days to weeks in ~60% of cases) or permanent; drug-induced nephrogenic DI may partially reverse after drug discontinuation [9][31-32]

References

1. Diagnosis and Management of Central Diabetes Insipidus in Adults. — Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson CJ. The Journal of Clinical Endocrinology and Metabolism. 2022.

2. Central and Nephrogenic Diabetes Insipidus: Updates on Diagnosis and Management. — Flynn K, Hatfield J, Brown K, Vietor N, Hoang T. Frontiers in Endocrinology. 2024.

3. Approach to the Patient With Suspected Hypotonic Polyuria. — Newell-Price J, Drummond JB, Gurnell M, et al. The Journal of Clinical Endocrinology and Metabolism. 2025.

4. Arginine Vasopressin Deficiency: Diagnosis, Management and the Relevance of Oxytocin Deficiency. — Atila C, Refardt J, Christ-Crain M. Nature Reviews. Endocrinology. 2024.

5. Rapid-Onset Hypernatremia Induced by Central Diabetes Insipidus Leading to Osmotic Demyelination Syndrome: A Case Report. — Zhang Y, Chen R, Kong X, Yan Y, Su S. Frontiers in Medicine. 2024.

6. A Novel Diagnostic Score for Diagnosing Arginine Vasopressin Deficiency (Central Diabetes Insipidus) or Primary Polydipsia With Basal Laboratory and Clinical Parameters: Results From Two International Multicentre Prospective Diagnostic Studies. — Atila C, Chifu I, Drummond JB, et al. The Lancet. Diabetes & Endocrinology. 2025.

7. Diagnosis and Management of Diabetes Insipidus for the Internist: An Update. — Christ-Crain M, Winzeler B, Refardt J. Journal of Internal Medicine. 2021.

8. Disorders of Salt and Water Balance After Pituitary Surgery. — Brooks EK, Inder WJ. The Journal of Clinical Endocrinology and Metabolism. 2022.

9. FDA Drug Label. — Updated date: 2023-10-02. Food and Drug Administration.

10. Diagnosis and Management of Sodium Disorders: Hyponatremia and Hypernatremia. — Miller NE, Rushlow D, Stacey SK. American Family Physician. 2023.

11. Neurohypophyseal diabetes insipidus. — National Library of Medicine (MedlinePlus) 2010.

12. Evaluation and Management of Diabetes Insipidus. — Adam P. American Family Physician. 1997.

13. The Diagnosis and Management of Diabetes Insipidus During Medical Emergencies. — Buonocore CM, Robinson AG. Endocrinology and Metabolism Clinics of North America. 1993.

14. Acquired Forms of Central Diabetes Insipidus: Mechanisms of Disease. — Verbalis JG. Best Practice & Research. Clinical Endocrinology & Metabolism. 2020.

15. Hypopituitarism. — Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S. Lancet. 2024.

16. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. — Fleseriu M, Hashim IA, Karavitaki N, et al. The Journal of Clinical Endocrinology and Metabolism. 2016.

17. Neuroimaging of Central Diabetes Insipidus-When, How and Findings. — Adams NC, Farrell TP, O'Shea A, et al. Neuroradiology. 2018.

18. Causes of Reversible Nephrogenic Diabetes Insipidus: A Systematic Review. — Garofeanu CG, Weir M, Rosas-Arellano MP, et al. American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation. 2005.

19. Drug-Induced Diabetes Insipidus: Incidence, Prevention and Management. — Bendz H, Aurell M. Drug Safety. 1999.

20. FDA Drug Label. — Updated date: 2024-12-06. Food and Drug Administration.

21. FDA Drug Label. — Updated date: 2021-09-01. Food and Drug Administration.

22. Management of Central Diabetes Insipidus. — Garrahy A, Thompson CJ. Best Practice & Research. Clinical Endocrinology & Metabolism. 2020.

23. New Developments and Concepts in the Diagnosis and Management of Diabetes Insipidus (AVP-deficiency and Resistance). — Angelousi A, Alexandraki KI, Mytareli C, Grossman AB, Kaltsas G. Journal of Neuroendocrinology. 2023.

24. Nephrogenic Diabetes Insipidus: A Comprehensive Overview. — Vaz de Castro PAS, Bitencourt L, de Oliveira Campos JL, et al. Journal of Pediatric Endocrinology & Metabolism : JPEM. 2022.

25. ENaC Inhibitors for the Management of Lithium Related Polyuria: A Systematic Review. — Strawbridge R, Ott M, Werneke U, et al. Journal of Affective Disorders. 2025.

26. Lithium-Induced Nephrogenic Diabetes Insipidus With Efficacy of Desmopressin in Combination With Thiazide Diuretics and Non-Steroidal Anti-Inflammatory Drugs: A Case Report With a Review of the Literature. — Jinnouchi T, Yoshimoto M, Ogino K, Oji T, Hayashi M. Internal Medicine. 2024.

27. FDA Drug Label. — Updated date: 2026-03-02. Food and Drug Administration.

28. Central Diabetes Insipidus From a Patient's Perspective: Management, Psychological Co-Morbidities, and Renaming of the Condition: Results From an International Web-Based Survey. — Atila C, Loughrey PB, Garrahy A, et al. The Lancet. Diabetes & Endocrinology. 2022.

29. Nephrogenic Diabetes Insipidus in Childhood: Assessment of Volume Status and Appropriate Fluid Replenishment. — Guarino S, Diplomatico M, Marotta R, et al. Pediatric Emergency Care. 2020.

30. Central Diabetes Insipidus in Children and Adolescents: Twenty‐Six Year Experience from a Single Centre. — Korkmaz HA, Kapoor RR, Kalitsi J, et al. International Journal of Endocrinology. 2021.

31. Identifying Risk Factors for Postoperative Diabetes Insipidus in More Than 2500 Patients Undergoing Transsphenoidal Surgery: A Single-Institution Experience. — Joshi RS, Pereira MP, Osorio RC, et al. Journal of Neurosurgery. 2022.

32. Importance of Intraoperative Factors in Postoperative Arginine Vasopressin Deficiency After Pituitary Adenoma Surgery. — Alidaei N, Sharifi G, Davoudi Z. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2024.

33. Arginine or Hypertonic Saline–Stimulated Copeptin to Diagnose AVP Deficiency. — Refardt J, Atila C, Chifu I, et al. The New England Journal of Medicine. 2023.

34. Diagnostic Accuracy of Copeptin in the Differential Diagnosis of the Polyuria-Polydipsia Syndrome: A Prospective Multicenter Study. — Timper K, Fenske W, Kühn F, et al. The Journal of Clinical Endocrinology and Metabolism. 2015.

35. Disorders of Water Balance. — Natascia Iorgi, Flavia Napoli, Giovanni Morana, et al. Brook's Clinical Pediatric Endocrinology, 7th Edition. 2019.

36. A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. — Fenske W, Refardt J, Chifu I, et al. The New England Journal of Medicine. 2018.

37. Arginine-Stimulated Copeptin Measurements in the Differential Diagnosis of Diabetes Insipidus: A Prospective Diagnostic Study. — Winzeler B, Cesana-Nigro N, Refardt J, et al. Lancet. 2019.

38. Clinical Review: Treatment of Neurohypophyseal Diabetes Insipidus. — Oiso Y, Robertson GL, Nørgaard JP, Juul KV. The Journal of Clinical Endocrinology and Metabolism. 2013.

39. Desmopressin Dose Requirements in Adults With Congenital and Acquired Central Diabetes Insipidus. — Pedersen AN, Andreassen M, Rasmussen AK, Krogh J. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 2024.